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The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi;
olaparib, Lynparza) for platinum–sensitive relapsed high–grade ovarian cancer with either germline or
somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to
patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing
for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of
breast or ovarian cancer. Furthermore, testing of tumor samples to identify the estimated 3%–9% of
patients with somatic BRCA1/2 mutations who, in addition to germline carriers, could benefit from PARPi
therapy is also now being considered. This new testing paradigm poses some challenges, in particular the
technical and analytical difficulties of analyzing chemically challenged DNA derived from formalin–fixed,
paraffin–embedded specimens. The current manuscript reviews some of these challenges and technical
recommendations to consider when undertaking BRCA1/2 testing in tumor tissue samples to detect both
germline and somatic BRCA1/2 mutations. Also provided are considerations for incorporating genetic
analysis of ovarian tumor samples into the patient pathway and ethical requirements.
& 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inc. This is an open access article u
, Centre for Cancer Research
Road, Belfast, BT9 7AE, UK.
.G. de Castro).1. Introduction
1.1. BRCA1/2: Associated cancer risk and genetic testing
BRCA1 (OMIM#113705) and BRCA2 (OMIM# 600185) genes
(chromosome 17q21 and 13q12, respectively) [1,2] are tumor
suppressor genes encoding proteins primarily involved in DNA
repair. Loss of function mutations in BRCA1/2 are associated withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lesser extent other cancers (eg, prostate cancer) [3,4]. Women
carrying a pathogenic germline mutation in either BRCA1 or BRCA2
have a substantially increased lifetime risk of developing BC and
OC: 40%–85% lifetime BC risk with BRCA1/2 mutations, with higher
rates in BRCA1 mutation carriers [5,6]. Similarly, for OC the lifetime
risk is estimated to be higher in women inheriting a BRCA1
mutation (25%–65%) compared with a BRCA2 mutation (15%–
20%) [5,6]. The precise cancer risk in female BRCA1/2 germline
mutation carriers and the factors that govern mutant allele
penetrance depend on many factors, including personal and/or
reproductive factors, mutation location, and as yet undefined
genetic factors (‘modifier genes’) [7,8].
Pathogenic BRCA1/2 variants are distributed along the entire
gene coding regions and overwhelmingly result in truncation and/
or inactivation of the mutant protein. Genetic variants include
nonsense, frameshift, splice-site, and some missense mutations, as
well as large deletion duplications and rearrangements [9,10].
Since the cloning of BRCA1/2 genes, individuals with a strong
family history of BC and/or OC have undergone oncogenetic
counseling and BRCA1/2 genotyping to identify germline mutation
carriers. In families where a pathogenic mutation is detected, the
mutation serves as a relevant tool for assessing lifetime cancer
risk. Asymptomatic, cancer–free female mutation carriers are
offered surveillance for early BC detection and the possibility of
risk–reducing surgery [11]. Mutation–carrying women are recom-
mended to undergo risk–reducing salpingo-oophorectomy
between 35–40 years of age (after childbearing) because of the
lack of a proven surveillance scheme impacting on survival for the
early detection of OC.
In 2015, the first poly (adenosine diphosphate-ribose) polymerase
inhibitor (PARPi; olaparib, Lynparza) was licensed for the treatment
of BRCA–mutated OC. In a Phase II clinical trial involving 265 patients
with either platinum–sensitive recurrent ovarian, fallopian tube or
primary peritoneal (high–grade) cancer, maintenance therapy with
olaparib showed an improvement in median progression–free sur-
vival (PFS). This improvement was more pronounced in patients
whose tumors had BRCA1/2 mutations; hazard ratio (HR) 0.18
compared with wild–type BRCA1/2 patients HR 0.54 [12]. More
recently, results of the phase III trial (SOLO-2; N ¼ 295) of olaparib
tablets as maintenance therapy in patients with relapsed germline–
mutated BRCA1/2 OC reported an HR of 0.25 for PFS of patients
receiving olaparib versus placebo, and an HR of 0.50 for time to
second progression or death for the olaparib versus placebo group
[13]. In another Phase III trial of the PARPi niraparib (the European
Network of Gynaecological Oncology Trial groups (ENGOT)-OV16/
NOVA trial) involving 553 OC patients, an HR of 0.27 for PFS was
observed for niraparib treatment compared with placebo in OC
patients with germline BRCA1/2 mutations; HR 0.45 for PFS in
wild–type BRCA1/2 mutation group and HR 0.38 for patients with
germline wild–type BRCA1/2 patients with homologous recombina-
tion deoxyribonucleic acid (DNA) repair deficient (HRD) tumors [14].
Poly (adenosine diphosphate-ribose) polymerase (PARP)
enzymes function in the repair of single–stranded DNA (ssDNA)
breaks via the base–excision repair pathway [15,16]. Therefore,
PARP inhibition results in an accumulation of ssDNA breaks; in
normal cells these become converted to double–stranded DNA
(dsDNA) breaks, which are repaired by the homologous recombi-
nation repair (HRR) pathway [15]. In cells lacking a functioning
BRCA1/2 protein, repair by the HRR pathway is also inhibited;
therefore, PARPi treatment of BRCA1– and BRCA2–associated can-
cers causes ‘synthetic lethality’ (when two non–lethal processes
combine to cause cell death) specifically to cancer cells [15,17,18].
Olaparib is licensed in the European Union as maintenance
therapy for adult patients with platinum–sensitive relapsed
BRCA1– and BRCA2–mutated (germline and/or somatic deleteriousmutations) high–grade serous (HGS) carcinoma of the ovary,
fallopian tube, or peritoneum, who are in complete or partial
response to platinum–based chemotherapy. Thus, OC patients are
now also referred for BRCA1/2 genetic testing to determine their
suitability for PARPi therapy, in the appropriate clinical context.
This new indication for BRCA1/2 genetic testing has also intro-
duced the concept of tumor testing of BRCA1/2 gene mutations, as
this approach can potentially capture both germline and somatic
BRCA1/2 pathogenic variants. As OC is the only indication for
which PARPi have been licensed thus far, the remainder of this
article will focus on BRCA1/2 tumor–based testing in OC.
1.2. Ovarian cancer treatment and impact of BRCA1/2 mutations on
treatment outcomes
Platinum and paclitaxel combination chemotherapy has been
the first–line standard of care for OC [19], with carboplatin
recently replacing cisplatin because it is equally effective and
better tolerated. Since 2011, bevacizumab has been approved in
Europe in combination with first–line standard of care treatment
of patients with advanced epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Nonetheless, advanced OC patient
prognosis remains poor, with a median PFS and 5–year overall
survival (OS) of 14–19 months and 30%–35%, respectively, (ICON
7 and GOG 140), and ultimately most patients will relapse [20–22].
Ovarian cancer comprises different histological subtypes, of
which high–grade serous (HGSOC) is the most common, repre-
senting ~70% of advanced cases [23–25]. In women unselected for
family history, germline BRCA1/2 mutations have been found in
4%–14% of all OCs, 5%–18% of serous OCs, and ~22% of HGS cases
[26–32].
Patients with germline BRCA1/2–mutated OC tend to respond
well to platinum–based chemotherapy and have a longer median
OS than sporadic OC patients [33–39]. The main histological
subtype associated with BRCA1/2 mutations and response to
platinum is HGS carcinoma. Other OC histological types have been
found to harbor deleterious mutations in other HRR genes [40];
31% of OCs have a deleterious germline (24%) or somatic (9%)
mutation in ≥1 of 13 HRR genes (mutations also associated with
primary platinum sensitivity and improved OS).
1.3. Somatic BRCA1/2 mutations in ovarian cancer
In the Phase II trial of olaparib in patients with platinum–
sensitive serous OC, 136 out of 265 patients had a BRCA1/2
mutation; 20 (15%) were somatically acquired [41]. In another
study, BRCA1/2 mutations were identified in 44 out of 235 (19%)
unselected OC tumors, 39% of which were somatic [27]. No addi-
tional somatic mutations were detected in tumors from patients
with germline mutations, suggesting that loss of heterozygosity
(LOH) is responsible in most cases for the bi–allelic inactivation in
neoplastic cells. Another study, by The Cancer Genome Atlas
(TCGA) consortium, of HGSOC patients found BRCA1/2 mutations
in 64 out of 316 (20%) patients: 9% and 8% were germline
BRCA1 and BRCA2 mutations, respectively, and 3% were somatic
mutations [42].
Whole exome sequencing analysis of the combined germline–
somatic landscape in OC in a series of 429 TCGA OCs found
germline truncation variants and large deletions across Fanconi
pathway genes in 20% of cases [43]. In this analysis, somatic
mutations in BRCA1 and BRCA2 with potential functional conse-
quences were detected in 4.9% and 2.6% of OCs, respectively.
An analysis of a large set of OC patients for germline (n ¼ 899),
somatic (n ¼ 279) and epigenetic alterations (n ¼ 482) in the
BRCA1, BRCA2 and RAD51C genes revealed deleterious germline
BRCA1 mutations in 32 (3.6%), BRCA2 in 28 (3.1%), and RAD51C in
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were observed in 3.6% of tumors.
Whether a deleterious mutation has been inherited or acquired
somatically, it is thought to be essential that the remaining BRCA1/
2 allele in 17q21 or 13q12, respectively, should be lost in the pre–
malignant cells for malignant transformation to occur. In OC tumor
samples with deleterious mutations in BRCA1/2, LOH of the func-
tional allele was detectable in virtually all cases with BRCA1
mutations [45–47] and in ~70% of cases with BRCA2 mutations.
These LOH events increase the allelic frequency of the mutation in
tumor samples.
1.4. Rationale for BRCA1/2 tumor testing
When using tumor tissue DNA to detect BRCA1/2 variants, both
germline and somatic BRCA1/2 mutations are identified. This could
be advantageous (time saving and cost saving), as potentially only
one test needs to be performed to identify all patients with
deleterious BRCA1/2 variants that may benefit from PARPi treat-
ment. An estimated 10%–20% of OC patients are likely to harbor
either a germline or somatic BRCA1/2 mutation; this approach
could facilitate a focused germline testing effort and overall
reduction in genetic testing.2. Considerations and Recommendations for Ovarian Cancer
Tumor BRCA1/2 Genetic Testing
Key recommendations for conducting BRCA1/2 genetic testing
on OC tumor tissue samples are summarized in Table 1.
2.1. Recommendations for BRCA1/2 tumor testing sample types
Ovarian cancers are characterized by a complex and changing
genetic profile [48]; consequently, BRCA1/2 tumor testing results
can potentially vary depending on disease stage and sample site.
There is also the possibility that a pathogenic germline or somatic
BRCA1/2 mutation can revert to a functional gene during disease
progression, due to development of acquired resistance via
somatic revertant mutations [49–54].
In a small study, secondary BRCA1/2 mutations were identified
in 7 out of 10 platinum–resistant OCs and 0 out of 5 platinum–
sensitive tumors, leading to the hypothesis that BRCA1/2 revertant
mutations could be associated with treatment resistance [55]. In
another study, a second BRCA1/2 mutation was found in 13 out of
46 (28.3%) recurrent OCs (12 of 13 were platinum resistant),
compared with 2 out of 64 (3.1%) primary tumors (one platinum
resistant, other unknown platinum response) [50]. A larger study
of 92 primary refractory, resistant, sensitive OCs and matched
acquired resistant disease used whole–genome sequencing of
tumor and germline DNA samples, and found several molecular
events associated with acquired resistance, including multiple
independent somatic BRCA1/2 revertant mutations [51].
The limited information available on somatic BRCA1/2 muta-
tions and response to PARPi from clinical trials relates to analysis
of primary ovarian tumors [12,41]. In light of this limited informa-
tion, it is suggested that BRCA1/2 tumor testing be performed on
primary tumors, as this is the most likely sample type available.
However, it should be noted that the analysis of metastatic tissue
at the time of progression may provide a more accurate indication
of tumors likely to respond to PARPi treatment, due to the
evidence supporting the association of revertant mutations and
treatment resistance. Surgeons responsible for OC patients need to
be made aware of the potential need for tissue testing further
down the line and thus the need for adequate collection of tumorsamples prior to surgery (ie, multiple biopsy specimens with a
high tumor content).
Formalin–fixed, paraffin–embedded (FFPE) specimens may be
used for BRCA1/2 mutation analysis; this is likely to be the most
widely available sample type. Fresh–frozen specimens provide
better quality DNA; however, they are not routinely available from
most referring centers. Other tissue treatments (eg, alcohol–based,
acidic or heavy metal fixatives, or decalcifying solutions) and
necrotic samples should be avoided, as they lead to increased
DNA degradation. The College of American Pathologists guidelines
for Human epidermal growth factor receptor 2 testing in BC can be
followed for the fixation of tissue samples [56]. The fixation time
should be 8–48 hours, depending on specimen or tissue block size;
prolonged cold ischemia time or a fixation duration o6 hours or
432 hours increases the likelihood of DNA being of suboptimal
quality and unsuitable for BRCA1/2 testing. Table 2 outlines
parameters to consider to ensure a good quality FFPE samples
for DNA analysis.
Formalin–fixed, paraffin–embedded sections for DNA extrac-
tion should be derived from a single representative block per case
and contain ≥30–50 μm depth (eg, 5 x 10 μm or 10 x 5 μm) tissue
sections. Appropriately trained pathologists should confirm diag-
nosis, determine the adequacy of specimens for BRCA1/2 genetic
testing by assessing neoplastic cell content in the specimen, and
mark the relevant areas of the tissue to guide macro-dissection as
required. Each laboratory should establish the minimum propor-
tion and number of neoplastic cells needed for mutation detection
during validation of the methodology. A set of dilutional standards
from cells with known BRCA1/2 pathogenic variants could be used
to assess the lower limit of detection.
2.2. Recommendations for DNA extraction from tumor samples
DNA for BRCA1/2 testing should be extracted from the tumor
tissue sample using a validated protocol that ensures sufficient
quality and quantity of DNA for the particular methodology, which
may widely differ. Tumor samples must have a sufficiently high
percentage of neoplastic cells to detect somatic mutations. Gen-
erally, a sample for BRCA1/2 tumor testing is recommended to
contain a percentage of neoplastic cells that is at least three times
the method’s limit of detection (eg, methodology with 5% limit of
detection requires the area of tumor sample selected for DNA
extraction to contain ≥15% neoplastic cells). This should allow for
overestimation of neoplastic cell content, particularly in samples
with large areas of inflammation and, to a lesser degree, account
for tumor heterogeneity.
The quantity of DNA analyzed can vastly influence result
accuracy (eg, analysis of 1 ng of DNA corresponding to the DNA
content from ~150 cells can lead to stochastic variation in the
sample, increasing the risk of false negative results when the
mutation–carrying alleles are not sufficiently represented in the
sample or are negatively selected during the process), or false
positive results (when artefactual sequences are predominantly
amplified during the process). Conversely, 100 ng of DNA corre-
sponds to the DNA content from ~15,000 cells, allowing for a
statistically representative sample of tumor DNA. Thus, increasing
the quantity and proportion of analyzed tumor DNA improves the
likelihood and accuracy of detecting somatic mutations. Although
FFPE samples with low tumor content may still allow for the
detection of germline mutations (present in all cells) it is always
recommended that specimens with sufficient tumor content be
analyzed to reliably detect acquired (ie, somatic) mutations.
DNA extraction protocols specific for FFPE tissue are recom-
mended, as they tend to account for the shorter average fragment
size compared with high molecular weight (HMW) DNA extraction
methods. Fluorometric quantification of DNA should be
Table 1
Key recommendations for conducting BRCA1/2 on ovarian cancer tumor tissue samples.
Recommendation Category Key recommendations
Sample types appropriate for BRCA1/2
tumor testing
Use tissue samples from either primary HGS carcinomas or related metastases; FFPE specimens or fresh-frozen specimens if
available
Follow The College of American Pathologists guidelines for breast cancer for fixation of tissue samples (Hammond 2010); fixation
time 8–48 hours, depending on size of specimen
FFPE sections (in total) should be ≥50 μm in depth derived from a single representative block per case, using
macrodissection to enrich the neoplastic content when needed
Diagnostic H&E stained slides, reviewed by appropriately trained pathologists with molecular pathology experience, should
be used for tumor assessment
Sample should contain a percentage of tumor cells that is at least three times the limit of detection of the method being used
(eg, if a method has a 5% limit of detection, the area of tumor sample selected for DNA extraction should contain at least
15% tumor cells)
DNA extraction from tumor samples Use a DNA extraction protocol specific for FFPE tissues, deparaffinisation process and recommended starting material should
be adhered to
Fluorometric quantification of DNA should be undertaken using intercalating dyes (ie, PicoGreen® or Qubit®) as these can
more specifically assess the amount of dsDNA in the sample than spectrophotometric methods
The quantity of dsDNA ranges from 10–200 ng depending of the procedure used for library preparation
Methodologies for tumor testing Laboratories should use BRCA1/2 test methods that are able to detect mutations in specimens with at least 50% cancer cell
content, although laboratories are strongly encouraged to use (or have available an external reference laboratory) more
sensitive tests that are able to reliably detect mutations in specimens with ≥10% variant allele frequency, corresponding to
10%–20% neoplastic cell content
NGS, not Sanger sequencing, should be used for analysis
Any method used should have been validated using FFPE tumor samples
Amplicons must be shorter when using DNA derived from FFPE material compared with blood samples, and ideally o150 bp
An average sequencing coverage of 500–2000 reads, considering sequencing coverage uniformity, is recommended to avoid
false negative assessment and enable detection of somatic mutations when using amplicon-based NGS; however, this is
dependent on the assay limits of detection, level of sensitivity desired, and the sample content of neoplastic cells
Avoiding false positive and false
negative results
Use duplicate analysis or repeat analysis from the same starting genomic DNA to eliminate artefacts and use sufficient input
DNA
Bioinformatics considerations Any pipeline established and validated on germline BRCA1/2 mutations needs to be validated for tumor mutations
Collated information is available via a public website that enables the user to search for available information on individual
BRCA1/2 genetic variants and their current classification of benign or pathogenic at http://brcaexchange.org/; ClinVar
Informed consent and ethical
considerations
Written information as well as a discussion on the implications for the patient and their families of the test result, which
may either be performed personally or via a host of telemedicine technologies, is highly recommended for patients
referred for testing
Informed consent from patients must be obtained in writing before undertaking germline testing
Individual countries vary in their recommendations and legal requirements, and all local criteria must be adhered to
Timing of testing Tumor testing for BRCA1/2 status should be undertaken in order that the result is available when it is clinically relevant to
the patient and should factor in the local turnaround time for testing, the potential need for genetic counseling and any
associated waiting time, together with other relevant considerations. However, BRCA1/2 status can influence all aspects of
treatment, thus ideally should be undertaken upon diagnosis
Abbreviations: dsDNA, double–stranded deoxyribonucleic acid; H&E, haematoxylin and eosin; HGS, high–grade serous; FFPE, formalin fixed paraffin embedded; NGS, next–
generation sequencing; OC, ovarian cancer
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quantity, and spectrophotometric quantification should be aban-
doned. The quantity of dsDNA required ranges from 10–200 ng
depending on the library preparation procedure used [57]. It is
essential to perform a DNA quality control upfront, to test qualityTable 2
Parameters to consider to ensure good quality FFPE samples for DNA analysis.
Parameter considerations Recommendations
Fixation method 10% buffered formalin
Fixation time 8–48 hours, depending on size of specim
Prevention of cross-contamination Replace knife blades before each new F
Use disposable plasticware to transfer s
Use of DNAzap wipes or bleach on
microtome blades
Should be avoided, as are likely to degr
Percentage of neoplastic cells 3 × the limit of detection of the method
Selection of tumor area Avoid areas of inflammation or immune
Thickness of section 5–10 µm sections are normally suitable.
Macro-dissection Careful dissection under a magnifier gla
coming off the slides
DNA extraction Any method including a purification ste
Use of decalcification Not advised – reduces DNA yield and qu
acidic decalcification
Abbreviations: DNA, deoxyribonucleic acid; EDTA, ethylenediaminetetraacetic acid; FFPand amplifiability of the DNA. Laboratories can consider using
validated library preparation kits with the in vitro diagnostic
device CE–marked certification for specific use of testing in FFPE
samples, if available. Use of standard DNA samples (commercially
available or in–house validated) as positive and negative controlsen
FPE tissue block is cut
ections to glass slides
ade DNA and inhibit PCR
infiltrate, areas of necrosis, and selecting many different small regions
The amount is dependent on the surface of the dissected area
ss is recommended. Pre-wet the scalpel or pipette tip to avoid flakes of tissue
p suitable for small DNA fragments can be used
ality. If decalcification is needed (ie, bone biopsies), EDTA must be used instead of
E, formalin fixed paraffin embedded; PCR, polymerase chain reaction
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performance over time. Alternatively, clinical samples with known
BRCA1/2 genetic status can be periodically included as controls.
Continuous evaluation of the employed procedure in the context
of an accreditation program (such as ISO15189 or equivalent), as
well as participation in certified external quality assessment (EQA)
programs specific for tumor BRCA1/2 testing from FFPE (ie, EMQN,
QuIP or UKNEQAS) is highly recommended.
2.3. Advantages and pitfalls of different methodologies for BRCA1/2
tumor testing
BRCA1/2 are both large genes, and mutations can occur any-
where along the coding region in most populations lacking
founder mutations [58]. Thus, it can be more challenging to detect
BRCA1/2 mutations than mutations in oncogenes with known
mutation ‘hot spots’ (eg, KRAS). Additionally, a significant propor-
tion of BRCA1 variants consists of large intragenic deletions or
rearrangements (≥8% of known BRCA1 mutations; 433% in some
northern European countries), which are generally more difficult
to detect in DNA derived from FFPE than in HMW germline DNA.
The proportion of BRCA2 large rearrangement is very low (o2%)
[59] and the proportion of these events that are acquired somati-
cally in OC tumors is still unknown. Moreover, the mutations with
an impact on splicing should be carefully checked using algorithms
(eg, MaxEntScan). Some variants may seem to have no functional
impact but in fact effect exon splicing (ie, exon 23 in BRCA1 [60])
and these events should be carefully analyzed [61,62]. Currently,
there is little information in the literature to inform the medical
community regarding the decision to test for BRCA1/2 mutations in
OC tumor tissue samples first and then blood, or vice versa. The
quality and yield of DNA extracted from FFPE tumors is poorer
than DNA extracted from blood and fresh tissue, and tends to be
variable [63,64]. FFPE tissue poses specific diagnostic challenges,
and fragment sizes of DNA extracted from FFPE tumor tissue is
lower, requiring specific adjustment of diagnostic procedures,
including expert handling of tissue specimen for DNA extraction,
amplicon composition, and diagnostic evaluation. Laboratories
should use BRCA1/2 test methods that are able to detect mutations
in specimens with at least ≥10% variant allele frequency, corre-
sponding to a minimum content of 10%–20% neoplastic cells.
Next–generation sequencing (NGS) is highly recommended as
the sequencing method of choice for BRCA1/2 tumor testing, due to
the quantity of DNA available from tumor samples and the size ofTable 3




Little sample input (DNA from small biopsies)
Defined target regions
Improved inter–center comparability
Higher on target reads
Faster sample preparation
Simpler workflow and easier bioinformatics
Lower complexity in library preparation
Capture–
based NGS
Potential to detect large deletions/ rearrangements (depending o
the captured area)
Fixation artefacts and/or PCR duplicates are reduced
Higher coverage uniformity
Possibility to determine amount of unique reads and thus to asse
experimental limit of detection
Performed better with respect to sequencing complexity and
uniformity
Less likely than amplicon–based NGS to generate false positive SN
Abbreviations: DNA, deoxyribonucleic acid; NGS, next–generation sequencing; PCR, polBRCA1/2 coding regions and amplicon composition (160–220
amplicons per test and ideally o250 bp). Sanger sequencing
should be abandoned in tumor testing, as it is not sensitive enough
for tumor tissue sample analysis, especially in samples with o50%
tumor cells, and it also requires a large amount of DNA for the
screening of these two large genes. Established methods used for
detecting germline BRCA1/2 mutations from blood samples may
not be suitable for tumor tissue testing; it is therefore imperative
that any method used must be validated for use on FFPE samples.
Amplicon–based NGS approaches for analysis of FFPE material are
now commercially available, although each laboratory should
internally validate the specific complete pipeline.
The accuracy of tumor BRCA1/2 testing is influenced by multiple
variables, including the specimen’s percentage of neoplastic cells
and the sensitivity, specificity, and lower limit of detection, as
previously discussed. It is important to note that when using
amplicon–based sequencing strategies, the number of unique
template molecules analyzed is easily overestimated, especially if
the amount or quality of input DNA is suboptimal; therefore,
extreme care needs to be taken in the analysis of such samples.
The methods used to detect larger deletions or duplications may
not directly translate from germline analysis of HMW DNA to FFPE–
derived DNA analysis, due to smaller DNA fragment size, DNA
chemical modification, chromosomal copy number changes (ie,
aneuploidy), and the frequent instability of tumor samples [65].
Furthermore, the frequency of somatically acquired deletions and
rearrangements in tumor tissue is unknown; larger cohort studies
are required. Bioinformatic approaches using NGS data analysis of
copy number variation from capture–enrichment strategies are
recommended for identification of large deletions and duplications,
if previously validated. Multiplex ligation–dependent probe ampli-
fication is a commonly used method for detecting large genomic
rearrangements in germline DNA. However, it may not be appro-
priate for use without adaptation in tumor tissue analysis, as the
control reference regions are not suitable to use in the calculations
due to aneuploidy present in the tumor cells. Using normalization
with intragenic probes allows for detection of intragenic exon
deletions and duplication [47]. Such methods need to be extensively
validated in the laboratory if all types of variants need to be
detected in the tumor sample. Point mutations and small indels
are best identified using amplicon and capture–based NGS [66], the
advantages and disadvantages of which are outlined in Table 3. An
average sequencing coverage of 500×–2000× reads, considering
sequencing coverage uniformity is recommended to avoid falsefor analysis of tumor tissue samples.
Disadvantages
Fixation artefacts/PCR duplicates
Very difficult to detect large deletions/rearrangements
Lower coverage uniformity
Mutations at amplicon ends might be problematic
Impossible to calculate experimental limit of detection of the assay as
unique coverage is generally unknown





More sample input required (× 10)
Longer and more laborious methods
Increased turnaround times
More data output (more detected genomic aberrations and/or
interpretation might be more difficult)
Complexity of library preparation
ymerase chain reaction; SNV, single nucleotide variants
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when using amplicon–based NGS; however, this is dependent on
the level of sensitivity desired and the sample content of neoplastic
cells. It should also be noted that the number of reads does not
necessarily correlate with sensitivity, as many reads may be derived
from a single template molecule (ie, polymerase chain reaction
[PCR] duplicates). Using a method with single molecule tags over-
comes this problem [47]. Moreover, it also depends on the amount
of samples loaded onto the sequencer, the type of reagents or chips
used for sequencing, and the type of instrument.
Any assay used clinically should be validated in terms of
specificity, sensitivity, limit of detection, repeatability (intra–batch
variation), and interim precision (inter–batch variation). Labora-
tory–developed tests need to be fully validated, and commercially
available tests also require verification at least (if they are used
according to manufacturer’s instructions). Assay validation and
verification must be performed on typical sample types; in the
case of tumor BRCA1/2 testing, typical samples are OC FFPE,
including biopsies and resection specimens. Ideally, a range of
typical DNA yields should be evaluated to determine optimal
conditions, and to determine any potential assay performance
issues if suboptimal conditions are used (eg, low DNA input where
artefacts are often more apparent) [67]. In Germany, the Institute
of Pathology and Germany's National Accreditation Body (DAkkS)
can provide validation, and DAkkS guidelines according to ISO
17020 are available for assay validations. In most other countries,
ISO15189 accreditation is necessary.
An EQA testing exercise, involving a number of central Euro-
pean countries, has demonstrated broad, high–quality diagnostic
availability of NGS–based BRCA1/2 mutation testing on FFPE tumor
tissue in 420 centers, providing broad community–based avail-
ability of the test [68]. This trial has also shown the diagnostic
usefulness of the commonly available NGS platforms and the
feasibility of NGS–based testing within time spans required in
oncological patient care.
2.4. Avoiding false positive and false negative results
Due to the quality of the DNA extracted from FFPE tissue,
artefactual errors caused by the fixation process can result in false
positive results. Duplicate analysis or repeat analysis from the
same starting DNA can help eliminate artefacts, as they are not
generally reproducible due to their stochastic nature [67]. Artefacts
can also be reduced if the method being used can discriminate
between sense and antisense strands, and/or involve molecular
barcodes, which have the additional benefit of being able to assess
the number of template molecules analyzed [69–72]. These
artefactual errors are a particular issue for amplicon–based
sequencing, when DNA concentration is low [67,71], as the rate
of PCR duplicates increases with decreased DNA input amounts.
This is relevant for FFPE tumor biopsy samples, as the number of
PCR duplicates is expected to be higher due to limited specimen
material that restricts DNA input amounts and poor sample quality
that limits the amount of DNA that can be amplified. However,
provided DNA input for the assays is sufficient, many artefacts can
be screened out by filtering out variants with an allele frequency
o5%–10%, depending on neoplastic cell content. Mutations should
pass quality checks and filter settings, and repetitive variants or
artefacts in many samples on the same sequencing run should be
excluded.
2.5. Bioinformatics considerations
The bioinformatic process, used to analyze and interpret BRCA1/
2 mutational analysis results, is a critical part of the whole testing
process and requires as much consideration, validation, andaccreditation (eg, ISO15189 or CLIA) as the laboratory methods
selected to perform the BRCA1/2 mutation analysis. Individual
samples in a pooled reaction must be identified and de–multi-
plexed according to the indices used in the library preparation and
the raw data aligned to the reference sequence. Any variations
between the reference sequence and the test samples need to be
identified by appropriate variant–calling algorithms, correctly
annotated using human genome variant society (HGVS) nomen-
clature, and classified through interrogation of internal and exter-
nal databases (list provided in Appendix A). Bioinformatics
pipelines are therefore a complex mix of different tools tailored
to fit the laboratories in their BRCA1/2 testing process. A pipeline
established and validated on germline BRCA1/2 testing may not be
suitable or may require modification for tumor–tissue–based
BRCA1/2 testing or for testing in a different laboratory with a
different methodology, mainly due to the length of amplicons
obtained through library design.
Pipelines are typically composed of a combination of commer-
cial software, open–source third–party software and bespoke
elements. The amount of validation previously conducted on each
of these components is likely to vary; however, commercially
available solutions should have undergone some level of verifica-
tion and so may require less in–house testing. Commercial
solutions may be particularly useful for testing laboratories with
little or no bioinformatics support. Information security manage-
ment is important where sensitive information is shared, such as
in database queries or variant annotation processes, and local and
international legislation relating to this issue must be adhered to.
The ISO 27001 is an internationally recognized best practice
framework for an information security management system,
which is important for bioinformatics platforms that share infor-
mation among users or manage information from clinical
scenarios.
Mutation detection threshold levels that are suitable for detect-
ing germline mutations will need to be modified to detect
potentially low–variant frequencies of somatic mutations. There
is no set recommendation to where this level should be, as this
depends on the performance criteria for the test, including any
pre–analytical steps such as DNA yield, test DNA input, and
neoplastic cell content.
The bioinformatics processes should be validated on all BRCA1/
2 mutation types. If laboratories do not have access to a sufficient
spectrum of data, there is an increasing repository of NGS data in
the public domain. This data could be a useful tool to ensure that
all variants are being identified, characterized and classified using
a laboratory’s own pipeline. There are a number of international
initiatives for the sharing of genetic data: ENIGMA is a consortium
of investigators focused on determining all unclassified variants
and variants of unknown significance (VUS) in BRCA1 and BRCA2.
The BRCA Challenge is a joint initiative of the Global Alliance for
Genomic and Global Health and the Human Variome Project,
involving several hundred institutes and academic organizations
around the world, which aims to pool global available data on
BRCA1/2 genetic variants to further the understanding of BRCA1/2
genetic variation.
2.6. Reporting tumor BRCA1/2 results
Recommendations for information to include when reporting
BRCA1/2 testing results are listed in Table 4.
The minimum dataset required in a clinical report for tumor
BRCA1/2 testing should include:• Suitability of the tumor sample, including neoplastic content
estimation, cellularity, and whether these are acceptable for the
specific testing method
Table 4
Recommendations for information to be included when reporting tumor BRCA1/2 results.
Information to include Comments
Histology and grade of the tumor If available and not previously performed
Percentage of neoplastic content in the analyzed sample
and if macrodissection has been performed
Defined as the percentage of neoplastic cells out of the total nucleated cells in the area used for DNA
extraction
Procedure used eg, NGS or Sanger sequencing
Coverage of the analysis Prevalent mutations vs the recommended whole coding regions including flanking intron sequences
Panel used Commercial or on demand or multipanel gene (eg, panels including more than BRCA1/BRCA2 genes)
Minimum coverage and guaranteed analytical sensitivity
with the employed methodology
Any regions for which there was insufficient sequencing read coverage (eg, 33 reads, dependent on assay
limits of detection) should be declared to avoid false negative assessment
If the analysis includes all types of alterations or just
single point mutations or small indel alterations
eg, ‘large rearrangements/deletions cannot be detected using this methodology’
Sequencer Models include: MiSeq, NextSeq 500, PGM, IonProton
Bioinformatic tools employed Freeware or commercial; indicate if they have been validated or not for this type of analysis. If the tools
are web based, include the https address
Requested databases for grading of detected mutation UMD and ClinVar-DB, etc.
Variant allele frequency It is important to correlate with neoplastic tumor content and potential LOH, which is present in the vast
majority of cases
Explanation of therapeutic consequence of mutations
according to the classification of the variants
Mutation class 4 or 5 ~pathogen ¼ possibility of therapy with PARPi; mutation class 1–3 or wild
type ¼ no therapeutic consequence and should not be reported (see text for VUS)
A recommendation of germline analysis and genetic
counseling in cases of pathogenic mutations
Germline analysis should be always considered if not already performed
Accreditation of the laboratory ISO15189, CAP, CLIA or equivalent
Participation in EQA For example: EMQN, QuIP, UK NEQAS
Abbreviations: CAP, College of American Pathologists; CLIA, Clinical Laboratory Improvement Amendments; DNA, deoxyribonucleic acid; EMQN, the European Molecular
Genetics Quality Network; EQA, external quality assessment schemes; LOH, loss of heterozygosity; NGS, next generation sequencing; PARPi, poly (adenosine diphosphate-
ribose) polymerase inhibitor; PGM, personal genome machine; QUIP, Arbeitsgruppe für Qualitätssicherung in der Molekularpathologie der Österreichischen Gesellschaft für
Pathologie; UK NEQAS, United Kingdom National External Quality Assessment Service; UMD, Universal Mutation Database; VUS, variants of unknown significance
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• The regions covered for each gene (eg, coding region only or
intronic and exonic regions)
• Overall results: either pathogenic or deleterious variants
present or absent
• Mutation details (when present): cDNA and amino acid change
according to HGVS nomenclature
• Reference sequence, including version used for annotation and
HGVS nomenclature
• Summary and interpretation: including pathogenic or likely
pathogenic classification of the identified variants. Non–patho-
genic variants should not be reported, although the laboratory
may keep a record of these. Variants of unknown significance
should be reported separately and clearly indicate the lack of
sufficient clinical or biological evidence. Information regarding
the potential therapeutic implications should be included when
possible.
2.7. Should genetic testing be limited to BRCA1/2 testing?
Currently, genetic testing in OC should be limited to BRCA1/2 for
clinical– and therapeutic–driven decisions, as indications to date
are restricted to these genes. However, additional genes involved
in the HRR pathway are being evaluated in a number of clinical
trials (NCT02422498, NCT02489058, and NCT01434316) and are
likely to become part of the standard testing methodology in the
future [73]. A recent study has shown increased efficacy of PARPi
in OC with HRD without a germline BRCA1/2 mutation [14].3. Integrating BRCA1 and BRCA2 Tumor Testing In The Patient's
Pathway
Commissioning strategies in different countries relating to both
BRCA1/2 tumor and germline testing are diverse. In October 2014,
the Society of Gynecological Cancer recommended that all women
diagnosed with ovarian, fallopian tube, or peritoneal carcinoma,regardless of age or family history, should receive genetic counsel-
ing and be offered BRCA1/2 genetic testing [74]. Many individual
country guidelines now also recommend offering BRCA1/2 genetic
testing to OC patients irrespective of a family history of BC or OC,
an approach that may in fact be cost-effective for universal
healthcare systems [75] (Appendix B) [11,76–84]. Although the
prevalence of BRCA1/2 pathogenic variants is highly associated
with a familial history, with a 475% probability of a mutation in
womenwith a strong BC or OC familial history [85], the availability
of PARPi and lack of accurate family history for many patients
make it appropriate to refer all OC patients for genetic testing.
3.1. Germline v tumor BRCA1/2 testing from the clinical perspective
It is necessary to determine the BRCA1/2 status of an OC patient
in order to be able to determine eligibility for PARPi therapy, and
testing the tumor samples can in principle detect both somatic and
germline variants. The limitations of tumor testing must, however,
be considered. It is difficult to distinguish between germline and
somatic mutations by analyzing tumor tissue in isolation and it is
therefore inappropriate to draw any conclusions concerning fam-
ilial risk based on this analysis alone. Any patient found to have a
deleterious BRCA1/2 mutation in a tumor specimen should be
offered genetic counseling to undergo germline analysis to assess
the existence of the mutation in germline DNA, a finding affecting
familial risk. On the other hand, genetic analysis in blood samples
can only identify germline mutations, missing approximately 3%–
5% of patients who have an acquired BRCA1/2 pathogenic variant
[12,41] and who could also benefit from PARPi therapy. The
advantages and disadvantages of BRCA1/2 tumor testing versus
blood germline testing are outlined in Table 5.
3.2. When in the patient journey should BRCA1/2 testing be carried
out?
Tumor testing for BRCA1/2 status should be undertaken in order
for the result to be available at a clinically relevant time frame,
Table 5
Advantages and disadvantages of BRCA1/2 tumor testing versus blood germline testing.
Tumor BRCA testing Blood BRCA testing
Advantages Can detect both somatic and germline mutations
Identifies a greater number of patients who may benefit from PARPi therapy
Potentially requires less extensive genetic counseling at the outset, and less involvement
for the wider family
Reverted BRCA1/2 mutations can identify patients resistant to treatment
Validated methods are available and professionals are
experienced in testing and interpreting variants
Patient protocols, pathways and procedures are well
established
Evidence is strong for the association between BRCA
germline mutations and response to PARPi therapy
Sample is easily obtained and contains high–quality
DNA
Analysis feasible in 100% of cases
Disadvantages Validated methods not yet widely available
Types of mutations not well defined
Only preliminary data are available on the response to PARPi associated with somatic
mutations
Sample with sufficiently high percentage of tumor cells/quality of DNA may be hard to
obtain, leading to the need for repeat testing and/or biopsy
Analysis not always possible for technical reasons. Investment in new NGS technology
may be required as most traditional methods are unsuitable due to limited DNA
Requires additional expertise in pathology to determine sample adequacy
Does not identify patients with somatic mutations
who could benefit from PARPi therapy
Genetic profile of the tumor may change with
disease progression and chemotherapy
Abbreviations: NGS, next–generation sequencing; PARPi, poly(adenosine diphosphate-ribose) polymerase inhibitor
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for genetic counseling, and other relevant considerations
(Figure 1). Referral timing for OC patients’ genetic testing is not
specified in many guidelines, but where it is, it is either recom-
mended at diagnosis (Italy [76,82]) or as soon as possible during
the first treatment cycle (Austria [83]; Belgium [77]). Given the
experience thus far in germline BRCA1/2 testing in OC and micro-
satellite instability testing of colorectal cancer patients for Lynch
syndrome, most patients are willing to undergo testing early on in
their management pathway.
Obtaining a tumor tissue sample for BRCA1/2 genetic testing
earlier on in the patient pathway may be advantageous. When
testing is for treatment decisions, it is desirable to have the test
within a maximum of 30–40 day of requesting. For countries
considering BRCA1/2 testing to be initially tumor–based rather
than germline–based, a proportion of OC patients may never
undergo BRCA1/2 testing if testing is limited to the time when
PARPi may be used (eg, patients that do not fulfil the approved
indication or have unsuitable tissue specimens or are deceased
prior to tumor testing). And for those OC patients in this latter
group who may harbor a germline mutation, a lack of BRCA1/2
genotyping may have grave implications for family members.
All of the above considerations should of course be reviewed if
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Figure 1. Timeline of factors to consider when deter3.3. Informed consent and ethical considerations
Tumor testing for somatic mutations to better define therapeu-
tic options is a well–accepted concept and practice in the manage-
ment of other malignancies (eg, EGFR and ALK testing in lung
cancer or KRAS and NRAS in colorectal cancer). However, these
mutations and genetic variants are clearly somatic by nature and
do not have any ethical ramifications. BRCA1/2 tumor tissue
genotyping poses different challenges given that an identified
tumor BRCA1/2 mutation may represent a germline BRCA1/2
mutation in the majority of cases. Therefore, it is important that
patients are adequately counseled prior to testing regarding both
the personal clinical implications of the test results and the
possible impact of BRCA1/2 genotyping on asymptomatic family
members. Informed patient consent and/or institutional review
board approval is, at least to some degree, required prior to
performing any genetic analysis.
The legal framework in different countries for the performance
of genetic testing is heterogeneous. Germline genetic testing is
protected or restricted by law and pre–test genetic counseling is
mandatory in many countries. Counseling for germline BRCA1/2
testing is traditionally performed by genetic counselors or medical
geneticists who specialize in oncogenetics. Due to increased
demand on services, some European centers have adopted an
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oncology unit, with support from the genetic department, pro-
vided by gynecologists or oncologists with training in Germany
and Austria [83] and oncologists with specialist training in the UK
[86]. Advanced Nurse Practitioners and Clinical Nurse Specialists
are another integral part of the oncology team, who, with the
support of the genetics and/or oncology team, are now also
involved in patient consenting for testing of somatic or germline
BRCA1/2 mutations [87]. For tumor BRCA1/2 testing, counseling
and obtaining consent in the context of oncology clinics is likely to
be a more practical option than referring all patients for pre–
surgical genetic counseling at the relevant genetics institute.
Because of this ever increasing need, it is likely that new models
of counseling will be adopted in the near future [88]. Appropriate
pre–test counseling is required prior to testing even if analysis is
only initially being performed on a tumor tissue sample, because
germline testing should be offered to the patient and family
members in the event that a mutation is detected. When a
hereditary OC is identified, the patient’s relatives have possibilities
for prevention and should be informed about undergoing genetic
testing and treatment options, particularly prophylactic surgery.
This type of genetic counseling is also required to be non-directive
in several countries (eg, Austria, Germany, Netherlands).4. Conclusion
With the recent approval of olaparib for platinum–sensitive OC
with BRCA1/2 deleterious mutations, a review in BRCA1/2 testing
strategy is warranted in most countries. The current paper
reviewed the different national and local strategies for BRCA1/2
testing, in particular how germline testing may now be offered to
all women with OC based on a 410% prevalence of BRCA1/2
mutations in this unselected population, raising to 415% in
patients with HGSOC. Based on the European license for olaparib,
genetic testing of tumor samples is needed to capture all possible
patients that may benefit from PARPi treatment. This new testing
paradigm poses some challenges, in particular the technical and
analytical difficulties of analyzing chemically challenged DNA
derived from FFPE specimens.
The question of whether germline or tumor testing needs to be
performed in sequence or in combination will likely be answered
differently in different countries, as such strategy is impacted by
local or national regulatory elements as well as existing clinical
pathways. In any case, identification of deleterious BRCA1/2 muta-
tions in tumor tissue requires subsequent germline testing to
assess the inheritability of such variation after appropriate genetic
counseling. Moreover, cascade testing of relatives of patients with
a germline mutation should be available. Similarly, OC patients
without deleterious germline BRCA1/2 mutations will require
tumor testing to identify the additional 3%–9% of patients that
could benefit from PARPi. Tumor BRCA1/2 testing is currently
available in most European countries by different methodologies,
although all of them make use of the current NGS technology
available. It is important to note that stringent validation of both
the NGS methodology and the bioinformatics pipelines for analysis
of NGS data derived from FFPE–extracted DNA is required, as this
poses different challenges to germline testing, including the
influence of neoplastic cell content in the variant allele frequency
and the potential artefacts derived from chemical modification of
the DNA during the processing of the specimen.
Regardless of the testing algorithm and methodology chosen, it
is paramount that any change in practice is linked to the patient’s
pathway to ensure that all patients have access to the tests
required for their care. This means both germline and tumor
testing need to be taken into consideration when designing anew testing strategy, as there is a risk of patients missing
important information if one of the tests is not performed as and
when appropriate. Such pathways would likely be affected by the
requirements for informed consent prior to germline and/or tumor
testing, and national and international policies and guidelines will
be required to establish best practice for OC patients in the context
of PARPi therapies. Furthermore, new scientific evidence regarding
the potential benefit of PARPi for OC patients without BRCA1/2
mutations, but with deleterious variants in other HRR genes, is
becoming available, and clinical trials assessing the value of other
biomarkers are being performed. It is therefore likely that a
completely new and comprehensive testing strategy will be
required in the next few years for the clinical management of OC
patients, in line with the advances of precision medicine in other
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